ArticleThrombosis and haemostasis2015
Polyphosphate accelerates factor V activation by factor XIa.
Article in Thrombosis and haemostasis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- Modeling the role of platelet-released polyphosphates in tissue factor-initiated coagulation under flow.Research and practice in thrombosis and haemostasis · 2026Article
- Review
- Serum Proteomics Reveals Systemic Responses inPathogens (Basel, Switzerland) · 2025Article
- The physicochemical properties of lipopolysaccharide chemotypes regulate activation of the contact pathway of blood coagulation.The Journal of biological chemistry · 2025Article
- Inhibitors of Polyphosphate and Neutrophil Extracellular Traps.Seminars in thrombosis and hemostasis · 2024Review
- Protein purification via consecutive histidine-polyphosphate interaction.Protein science : a publication of the Protein Society · 2024Article
- Advances in the cellular biology, biochemistry, and molecular biology of acidocalcisomes.Microbiology and molecular biology reviews : MMBR · 2024Review
- Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.Blood advances · 2023Article
- Design of biopolymer-based hemostatic material: Starting from molecular structures and forms.Materials today. Bio · 2022Review
- Polyphosphate Activates von Willebrand Factor Interaction with Glycoprotein Ib in the Absence of Factor VIII In Vitro.International journal of molecular sciences · 2022Article
- Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases.International journal of molecular sciences · 2022Review
- Inflammation in Cerebral Venous Thrombosis.Frontiers in immunology · 2022Review
- Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate.Blood · 2021Article
- Mechanisms and biomarkers of cancer-associated thrombosis.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Platelet polyphosphate induces fibroblast chemotaxis and myofibroblast differentiation.Journal of thrombosis and haemostasis : JTH · 2020Article
- Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).Expert opinion on therapeutic patents · 2020Review
- Schistosomes can hydrolyze proinflammatory and prothrombotic polyphosphate (polyP) via tegumental alkaline phosphatase, SmAP.Molecular and biochemical parasitology · 2019Article
- From underlying chemistry to therapeutic potential: open questions in the new field of lysine polyphosphorylation.Current genetics · 2019Review
- Polyphosphate in thrombosis, hemostasis, and inflammation.Research and practice in thrombosis and haemostasis · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Factor Va enhances the rate of prothrombin activation by factor Xa by four to five orders of magnitude. Production of initiating levels of factor Va from its precursor, factor V, is a critical event early in haemostasis, as factor V exhibits negligible cofactor activity. While thrombin is the most potent physiological back-activator of factor V, the first prothrombinase complexes require a source of factor Va prior to thrombin generation. A recent study by Whelihan et al. (J Thromb Haemost 2010; 8:1532-1539) identified factor XIa as a candidate for the initial thrombin-independent activation of factor V, although this reaction was slow and required relatively high concentrations of factors V and XIa. Activated platelets secrete polyphosphate, which we previously showed to be potently procoagulant. We now report that polyphosphate greatly accelerates factor V activation by factor XIa, and that this is supported by polyphosphate polymers of the size secreted by activated human platelets. This finding provides additional evidence that factor XIa-mediated generation of factor Va may contribute to the initiation of haemostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.